Listing 7.17 Hematological Disorders Treated by Bone Marrow or Stem Cell Transplantation in 2026: The Automatic 12 Month CAL-Level SSDI Approval from Transplant Date, How Serious Post-Transplant Complications Extend the Disability Period, Which Cell-Based Gene Therapies for Sickle Cell and Thalassemia Now Medically Equal the Listing, and What Happens at the 12 Month Mark

By Anthony Albert, Benefits Research Director. Published July 23, 2026.

If you got a bone marrow or stem cell transplant for a hematological disorder, you are considered disabled under SSA rules for at least 12 consecutive months from the transplant date. This is one of the shortest and most user-favorable listings in the entire Blue Book. You do not need to prove functional limitation. You do not need to show any complications. The 12 month clock runs from the transplantation date, period.

Since April 2026, the Compassionate Allowances (CAL) program flags 7.17 automatically at the DDS level, which means most 7.17 claims move through initial adjudication in weeks rather than months. Per POMS DI 23022.404 (updated August 5, 2025), SSA recognizes that the immune system remains impaired for up to 12 months post-transplant and that patients face high risk of relapse, new organ damage, or severe infections during that window. Complications do not have to occur for CAL to apply.

This article covers the exact 7.17 text, how allogeneic and autologous transplants are treated differently (mostly for cancer under 13.28, not for hematological disorders under 7.17), how serious complications extend the disability period past 12 months, which cell-based gene therapies now medically equal 7.17, pediatric 107.17 rules, and what actually happens at the 12 month review. Four worked cases at the end.

The Listing 7.17 Text

What "hematological disorders" means here

7.17 applies to non-cancer blood disorders treated with hematopoietic stem cell transplantation (HSCT). The most common conditions that route through 7.17 include:

• Aplastic anemia (severe or very severe)
• Myelodysplastic syndromes (MDS), including MDS-EB1 and MDS-EB2
• Sickle cell disease (HbSS, HbSC, sickle beta thalassemia)
• Beta thalassemia major
• Paroxysmal nocturnal hemoglobinuria (PNH)
• Congenital immune deficiencies including SCID, CVID (in select cases), Wiskott-Aldrich syndrome, X-linked hyper-IgM syndrome
• Fanconi anemia and other inherited bone marrow failure syndromes (Diamond-Blackfan anemia, Shwachman-Diamond syndrome, dyskeratosis congenita, GATA2 deficiency)
• Chronic granulomatous disease (CGD)
• Osteopetrosis (infantile malignant form)
• Congenital sideroblastic anemia unresponsive to pyridoxine

If the transplant is for cancer (acute leukemia, lymphoma, multiple myeloma, CML, solid tumors), it is evaluated under Listing 13.28, not 7.17. The 13.28 rules are similar but not identical. See the paragraph on 13.28 below.

What "at least 12 consecutive months from the date of transplantation" means

SSA measures the 12 months from the actual transplant date, which is the date the stem cells or marrow are infused. This is documented in the transplant summary as day 0. For an allogeneic transplant, day 0 is the day the donor cells go into your bloodstream. For an autologous transplant, day 0 is the day your own previously collected cells are re-infused after conditioning chemotherapy.

The 12 month clock does not restart if you have a second transplant. If you had a first transplant that failed and needed a second, the 12 months runs from the more recent transplant date, but SSA may find continuous disability from the first date if evidence supports it. Under 7.00F, SSA does not restrict the onset of disability to the transplantation date. Earlier onset can be established based on medical evidence from the pre-transplant period.

What "consider under a disability" means

You meet the listing automatically. No functional testing. No wait for symptoms to develop. No proof of GVHD or infections. The transplant date and the diagnosis alone establish Step 3 approval. SSA's DDS reviewer verifies the transplant occurred and confirms the underlying diagnosis, and the claim is approved.

What "after that, evaluate any residual impairment" means

After the 12 month automatic window, SSA does not automatically terminate benefits. Instead, at the CDR (continuing disability review), SSA looks for any residual impairment. If you have GVHD, ongoing immunosuppression complications, deterioration of organ systems, or continued need for transfusions or infusions, those impairments get evaluated under their respective body system listings. If you have no residual impairment and have functionally recovered, benefits may terminate.

The CAL Flag and Why It Matters

Since 2015, Hematopoietic Stem Cell Transplantation has been on the Compassionate Allowances list. Under POMS DI 23022.404 (updated 2025-08-05), SSA treats the 12 month post-transplant period as CAL-level impairment. This means:

• Initial DDS review is expedited, typically 2 to 6 weeks rather than 3 to 6 months
• Standard documentation requests are streamlined
• Consultative examinations are usually not required
• The claim is flagged for CAL processing at intake if you or your representative note the transplantation on the initial application

The most important operational takeaway is that you should file the SSDI or SSI application as soon as your transplant date is scheduled, and clearly note "hematopoietic stem cell transplantation" or "bone marrow transplant" in the application. Attach the transplant admission notice or scheduled admission letter. This triggers the CAL flag and starts the expedited review before your transplant even occurs. Benefits are then paid retroactive to the disability onset date, which is often earlier than the transplant date itself.

When 7.17 Extends Past 12 Months: Serious Complications

Under 7.00F, SSA can find continued disability beyond 12 months when there are serious post-transplant complications. The rule lists three categories:

Graft-versus-host disease (GVHD)

GVHD occurs when donor immune cells attack recipient tissues. It affects an estimated 30 to 70 percent of allogeneic transplant recipients depending on donor match, conditioning intensity, and prophylaxis. Two forms:

• Acute GVHD typically appears within 100 days of transplantation and affects skin, gut, and liver. Grade III and IV acute GVHD carry high mortality and often require prolonged hospitalization. Grade III-IV acute GVHD is a common reason SSA extends disability past 12 months.
• Chronic GVHD typically develops after day 100 and can affect skin, mouth, eyes, liver, lungs (bronchiolitis obliterans), joints, and GI tract. Chronic GVHD requiring systemic immunosuppression is a strong basis for continued disability under the affected body system listings.

If you have chronic GVHD affecting the lungs, evaluation moves to Listing 3.02 chronic respiratory disorders. If it affects the skin extensively, evaluation moves to Listing 8.05 dermatitis or 8.06. If it affects the GI tract with malabsorption and weight loss, evaluation moves to Listing 5.08 weight loss. If it affects the liver with cirrhosis, evaluation moves to Listing 5.05 chronic liver disease.

Frequent infections from immunosuppression

Post-transplant patients on prolonged immunosuppression (calcineurin inhibitors like tacrolimus or cyclosporine, mTOR inhibitors like sirolimus, mycophenolate, corticosteroids, or newer agents like ruxolitinib for chronic GVHD) face high infection risk. Common post-transplant infections include CMV reactivation, EBV-related PTLD (post-transplant lymphoproliferative disorder), invasive fungal infections (Aspergillus, Pneumocystis), BK virus cystitis or nephropathy, and recurrent bacterial infections. Under 7.00F, frequent infections after immunosuppressive therapy support continued disability beyond 12 months.

Significant deterioration of organ systems

Transplant conditioning regimens (total body irradiation, high-dose chemotherapy) can cause chronic organ damage. Common late effects include cardiotoxicity (evaluate under 4.02 chronic heart failure), pulmonary toxicity (evaluate under 3.02), CKD from calcineurin inhibitor nephrotoxicity (evaluate under 6.03/6.04/6.05), hypothyroidism (evaluate under Section 9 endocrine referrals), infertility, and secondary malignancies. Any of these can extend disability under the affected body system listing.

Cell-Based Gene Therapies That Now Medically Equal 7.17

Per POMS DI 23022.404 (updated August 5, 2025), three FDA-approved cell-based gene therapies for sickle cell disease and beta thalassemia are treated as medically equal to Listing 7.17:

• Casgevy (exagamglogene autotemcel): FDA approved December 8, 2023 for sickle cell disease in patients age 12 and older, and January 16, 2024 for transfusion-dependent beta thalassemia. Uses CRISPR-Cas9 gene editing to disrupt the BCL11A enhancer, restoring fetal hemoglobin production. Requires a single infusion of edited autologous stem cells after myeloablative conditioning.
• Lyfgenia (lovotibeglogene autotemcel): FDA approved December 8, 2023 for sickle cell disease in patients age 12 and older. Uses lentiviral vector to add a modified beta-globin gene (T87Q) to autologous stem cells. Also requires myeloablative conditioning.
• Zynteglo (betibeglogene autotemcel): FDA approved August 17, 2022 for transfusion-dependent beta thalassemia in patients ineligible for or without a matched sibling donor. Uses lentiviral vector to add functional beta-globin.

All three require myeloablative conditioning and cell reinfusion, which is functionally equivalent to autologous transplantation. The POMS specifically states that sickle cell disease or beta thalassemia treated with one of these three therapies generally medically equals Listing 7.17 (or 107.17 for children). The 12 month CAL-level clock runs from the date of cell infusion.

New gene therapies for other blood disorders are in late-stage trials as of mid-2026. SSA typically updates the POMS 6 to 18 months after each new FDA approval to add specific listing equivalence guidance.

Allogeneic vs Autologous: Why It Matters Less for 7.17 Than for 13.28

For hematological (non-cancer) transplants under 7.17, both allogeneic (donor cells) and autologous (your own cells) get the same 12 consecutive months from transplantation date. The distinction matters mostly under Listing 13.28 for cancer:

• 13.28A Allogeneic: at least 12 months from the transplantation date
• 13.28B Autologous: at least 12 months from the date of the first treatment under the treatment plan that includes transplantation, which is typically the induction chemotherapy several months before the actual transplant

Some patients ask which listing applies if they have both a cancer (like acute myeloid leukemia) and are receiving a stem cell transplant. The answer is Listing 13.28 governs. Cancer treated with transplant goes to 13.28. Non-cancer hematological disorder treated with transplant goes to 7.17. Do not double-list.

Pediatric Rule Under 107.17

For children, the parallel listing is 107.17. Text is identical to adult 7.17: at least 12 consecutive months from the transplantation date, with residual impairment evaluated under the affected body system. Children who receive HSCT for SCID, Fanconi anemia, sickle cell, or thalassemia all route through 107.17. Cell-based gene therapies (Casgevy, Lyfgenia) approved for patients age 12 and older also medically equal 107.17 per the same August 2025 POMS update.

What Happens at the CDR (12 Months Post-Transplant)

SSA schedules a Continuing Disability Review typically at the 12 to 18 month mark under Medical Improvement Expected (MIE) coding, which is the default for 7.17. Under POMS DI 26525.030, the diary for 7.17 cannot be set earlier than 12 months from the transplantation month.

At the CDR, SSA requests updated records including:

1. Recent transplant follow-up notes documenting engraftment, chimerism (for allogeneic), and any complications
2. Chronic GVHD assessments (NIH consensus criteria staging)
3. Immunosuppression medication list and duration
4. Recent labs (CBC with differential, complete metabolic panel, immunoglobulin levels, viral PCR panels for CMV/EBV/BK)
5. Pulmonary function tests if respiratory symptoms present
6. Cardiac imaging if cardiac symptoms present
7. Any hospitalizations for infection or complication

If you have ongoing GVHD requiring immunosuppression, ongoing organ deterioration, or ongoing transfusion dependence, benefits continue under the appropriate body system listing. If you have functionally recovered without residual impairment, benefits may terminate under 20 CFR 404.1594 medical improvement analysis.

Documentation Checklist

1. Pre-transplant medical records establishing the underlying hematological diagnosis. Bone marrow biopsy for aplastic anemia and MDS. Hemoglobin electrophoresis for sickle cell and thalassemia. Molecular testing for inherited marrow failure syndromes.
2. Transplant admission notice or scheduled admission letter. Anchors the CAL flag and lets you file before the actual transplant.
3. Operative or infusion procedure note documenting day 0 (the transplantation date). Signed by the transplant physician.
4. Discharge summary from the transplant admission.
5. Follow-up notes from the transplant center at day 30, day 100, and 6 months documenting engraftment, chimerism, and any complications.
6. GVHD staging notes if applicable (NIH consensus criteria for chronic GVHD).
7. Medication list showing conditioning regimen, GVHD prophylaxis, and post-transplant immunosuppression.
8. For gene therapy cases (Casgevy, Lyfgenia, Zynteglo), the pharmacy dispensing record, the cell manufacturing lot documentation, and the infusion procedure note.

Four Worked Cases

Case One, Rashida, 29, Georgia

Rashida has sickle cell disease HbSS diagnosed at birth. Multiple vaso-occlusive crises, two prior strokes, acute chest syndrome, and severe pain crises requiring monthly IV narcotic infusions. She received Casgevy on April 15, 2026 after conditioning with busulfan. She filed for SSDI on March 20, 2026 (before infusion) with the scheduled admission letter and prior sickle cell records. SSA approved her under 7.17 by medical equivalence to Casgevy per POMS DI 23022.404. Onset date was set at March 1, 2026 based on the pre-infusion severity. 12 month CAL-level window runs through April 14, 2027. CDR scheduled at 15 months.

Case Two, David, 47, Michigan

David has severe aplastic anemia unresponsive to ATG and cyclosporine. He received a matched unrelated donor allogeneic HSCT on January 8, 2026 after fludarabine/cyclophosphamide conditioning. Post-transplant course complicated by acute GVHD Grade III of skin and gut on day 45, treated with high-dose steroids and ruxolitinib. Chronic GVHD of lungs (bronchiolitis obliterans syndrome, FEV1 44 percent predicted) diagnosed at 8 months. He filed for SSDI on January 15, 2026. Approved under 7.17 CAL-level. At his 15 month CDR, chronic GVHD of lungs meets Listing 3.02 chronic respiratory disorders. Benefits continue under 3.02 rather than terminating.

Case Three, Ana, 4, California

Ana has severe combined immunodeficiency (SCID) diagnosed at 6 months of age through newborn screening (T-cell receptor excision circles). She received a haploidentical HSCT from her father at 8 months of age. Filed for SSI at diagnosis. Approved under 107.17 for automatic 12 month CAL-level disability. Post-transplant course complicated by CMV reactivation requiring 6 weeks of IV ganciclovir and BK viruria. Immune reconstitution slow, T-cell counts remain low at 12 months. At the CDR, ongoing immunodeficiency plus recurrent infections meet 114.07B under the pediatric immune deficiency listing. SSI benefits continue.

Case Four, Jordan, 33, New Jersey

Jordan has beta thalassemia major, transfusion dependent every 3 weeks since childhood, with iron overload complications including cardiomyopathy (LVEF 42 percent) and endocrinopathies. Ineligible for matched sibling donor. Received Zynteglo on September 20, 2025. Post-infusion course uncomplicated. At 12 months, hemoglobin stable at 12.5 g/dL without transfusion, LVEF improved to 51 percent. At the 15 month CDR, SSA finds functional recovery of the hematological condition. Residual cardiomyopathy at LVEF 51 does not meet 4.02 (requires LVEF 30 or less or specific MET or symptom criteria). Endocrinopathies from prior iron overload evaluated under Section 9 endocrine referrals do not meet an individual body system listing. Benefits terminate at month 18. Jordan can reapply if cardiomyopathy or endocrinopathies worsen.

Denial Counters

Denial reason: transplant was done less than 12 months before filing

7.17 does not have a look-back requirement. You are considered disabled from the transplantation date for 12 months. File as soon as possible, or even before the transplant if it is scheduled. The disability onset can be established earlier based on pre-transplant medical evidence.

Denial reason: DDS says the hematological disorder was not severe enough to require transplant

This is a rare denial rationale but occasionally happens when DDS second-guesses the treating hematologist. The counter is straightforward: the transplant was performed, meaning the treating team judged it medically necessary. Submit the transplant conference notes documenting the multidisciplinary decision to transplant. SSA generally defers to the treating team on this point.

Denial reason: no chimerism testing on file

Chimerism testing shows the percentage of donor cells in the recipient's marrow and blood, and is standard post-allogeneic transplant. Ask the transplant center for the day 30, day 100, and 6 month chimerism results. This is not a listing requirement, but it strengthens the file if the reviewer is questioning whether the transplant was successful.

Denial reason: gene therapy is not on the listing

Per POMS DI 23022.404 (updated 2025-08-05), Casgevy, Lyfgenia, and Zynteglo medically equal Listing 7.17 for sickle cell and beta thalassemia treatment. Cite the POMS reference in the appeal. The reviewer at reconsideration or ALJ level will typically apply the equivalence rule.

State Considerations

Transplant centers are federally regulated but concentrated in academic medical centers. Highest-volume adult HSCT centers include hospitals in Washington (Fred Hutchinson Cancer Center), Texas (MD Anderson), New York (Memorial Sloan Kettering, Weill Cornell), Massachusetts (Dana-Farber, Massachusetts General), Minnesota (University of Minnesota, Mayo), and Ohio (Cleveland Clinic, Ohio State).

For pediatric HSCT, top centers include Cincinnati Children's, Children's Hospital of Philadelphia, Boston Children's, St. Jude, Seattle Children's, and Texas Children's. Gene therapy for sickle cell is currently available at approximately 30 US centers as of mid-2026, with Casgevy Authorized Treatment Centers concentrated in high-volume sickle cell programs.

Related Blue Book Reading

• Listing 7.05 Hemolytic Anemias Including Sickle Cell
• Listing 7.10 Bone Marrow Failure Disorders
• Listing 7.02 Chronic Anemia (Historical + Current Rules)
• Listing 14.07 Immune Deficiency Disorders
• Listing 13.00 Cancer Overview (including 13.28)

Frequently Asked Questions